NC
TXG icon

NinePointTwo Capital’s 10x Genomics TXG Stock Holding History

NinePointTwo Capital’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,881
Closed -$272K – 327
2023
Q2 		$272K Buy
+4,881
New +$264K 0.11% 81
2022
Q3 		– Sell
-5,900
Closed -$266K – 228
2022
Q2 		$266K Buy
+5,900
New +$306K 0.09% 135

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

NinePointTwo Capital's TXG Position: Q3 2023 in Review

NinePointTwo Capital sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 4,881 shares — an estimated $272K sold.

NinePointTwo Capital first reported a position in TXG in Q2 2022 and held it in 2 quarters. The position peaked at $272K in Q2 2023. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

  • NinePointTwo Capital reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 4,881 10x Genomics shares in Q3 2023, an estimated $272K.
  • NinePointTwo Capital first reported a position in 10x Genomics in Q2 2022 and held it in 2 quarters.
  • NinePointTwo Capital's 10x Genomics position peaked at $272K in Q2 2023.
  • 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.